Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound medicine composite with breast cancer resistance function, application of composite and medicine based on composite

An anti-breast cancer and composition technology, which can be used in drug combinations, anti-tumor drugs, active ingredients of heterocyclic compounds, etc., can solve problems such as toxic and side effects

Active Publication Date: 2019-04-16
SHAANXI UNIV OF SCI & TECH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Doxorubicin (DOX), also known as doxorubicin, is an anthracycline antibiotic with anticancer effects extracted from fungal strains. It is a periodic non-specific anticancer drug and can effectively inhibit the synthesis of DNA and RNA. , has a killing effect on cancer cells in each growth cycle, for acute leukemia (lymphocytic and granulocytic), malignant lymphoma, breast cancer, ovarian cancer, bladder cancer, thyroid cancer, prostate cancer, testicular cancer, gastric cancer , liver cancer and other cancers have positive preventive and therapeutic effects, but it has certain toxic and side effects, especially cardiotoxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicine composite with breast cancer resistance function, application of composite and medicine based on composite
  • Compound medicine composite with breast cancer resistance function, application of composite and medicine based on composite
  • Compound medicine composite with breast cancer resistance function, application of composite and medicine based on composite

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] MTT assay was used to detect the effects of PL and DOX alone and in combination on the proliferation of breast cancer cells in vitro.

[0029] Take the MDA-MB-231 cells in the logarithmic growth phase, and press 3×10 per well 3 cells were plated in a 96-well plate. After culturing for 24 hours, the supernatant was discarded and administered according to the following groups. Both PL and DOX started at 40 μM and were serially diluted 2-fold. That is, the detection concentrations were 40, 20, 10, 5, 2.5, 1.25, 0.625, 0.3125, and 0.15625 μM, and DMSO was used as a negative control. Three replicate wells were set up in each group and cultured for 72 hours. Discard the supernatant, add 100 μl MTT working solution (0.5 mg / ml) to each well, and incubate for 3 h. Discard the supernatant, add 100 μl DMSO to each well, place on a micro-oscillator and shake for 10 minutes, then transfer to a microplate reader, and detect the OD value at 570 nm. Data calculates the survival rat...

Embodiment 2

[0033] Flow cytometry was used to detect the apoptosis-promoting effect of PL and DOX alone and in combination in breast cancer cells.

[0034] Take the MDA-MB-231 cells in the logarithmic growth phase, digest and resuspend them as a cell suspension, and press 5×10 5 cells were plated in a 6-well plate. After culturing for 24 h, the cells were divided into 4 groups: DMSO control group, PL single drug group (5 μM), DOX single drug group (0.5 μM), PL and DOX combined drug group (DOX / PL: 0.5 / 5 μM, that is, DOX and PL The molar ratio is 1:10), administered separately and acted for 48h. Cells in each well were collected, double-stained with Annexin V-FITC and PI staining solution at the same time, and incubated at room temperature for 15 min. Flow cytometry detects dual-channel fluorescence signals, the abscissa indicates the fluorescence signal intensity of the FL1 channel (FITC), and the ordinate indicates the fluorescence signal intensity of the FL2 channel (PI). The single p...

Embodiment 3

[0037] Nude mice tumor-bearing model administration experiment was used to detect the inhibitory effect of PL and DOX alone and in combination on breast cancer in nude mice.

[0038] Take 24 4-week-old female nude mice and place them in sterile mouse cages, and provide pure water and breeding feed, change the litter every other day, and start modeling after one week of feeding. Take MDA-MB-231 cells in logarithmic growth phase, digest and resuspend with PBS, inject 1×10 6 cells in its penultimate pair of mammary glands. When the tumor volume reaches about 50mm 3 At the same time, the nude mice were randomly divided into 4 groups, respectively DMSO control group, PL single drug group (4mg / kg), DOX single drug group (0.8mg / kg), DOX and PL combined drug group (DOX / PL: 0.8 / 4mg / kg, that is, the molar ratio of DOX to PL is 1:9). The four groups were intraperitoneally administered every other day, and the tumor volume and body weight of nude mice were measured before administrati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound medicine composite with a breast cancer resistance function, application of the composite and medicine based on the composite. The active content of the compound medicine composite is composed of doxorubicin and piperlongumine with the mole ratio of 1:5-1:15. According to an experiment, an MDA-MB-231 human breast cancer cell is used as a model, and through an MTTexperiment, by applying CompuSyn software analysis, it is discovered that a good synergistic effect is achieved during compatibility of doxorubicin and piperlongumine with the mole ratio of 1:10; through a cell apoptosis experiment, it is discovered that the apoptosis-promoting effect is obviously superior that that of a single medicine group when the two kinds of medicines cooperate for use; through a naked mouse cancer-bearing medicine application experiment, it is discovered that growth of heterograft tumors of MDA-MB-231 cells in the naked mouse can be effectively inhibited through a medicine cooperation application group, and the effect of the medicine cooperation application group is obviously superior that that of the single medicine group. In this way, medicine cooperation application of doxorubicin and piperlongumine has the high function of inhibiting the breast cancer through cooperation, and accordingly the composite has good clinical medicine application development prospects.

Description

technical field [0001] The invention belongs to the field of natural medicines, and in particular relates to a compound pharmaceutical composition with an anti-breast cancer effect, its application and the medicine based on the composition. Background technique [0002] According to statistics from the International Agency for Research on Cancer (IARC), it is estimated that there will be 18.1 million new cancer cases worldwide in 2018, and another 9.7 million cancer patients will die. According to the survey, the incidence of breast cancer accounts for 11.6%, ranking second among malignant tumors in the world, and its mortality rate is 6.6%, ranking fifth among malignant tumors in the world. According to the latest national cancer statistics released by the National Cancer Center, there are 3.804 million new cases of malignant tumors in my country, an average of more than 10,000 people per day. Breast cancer accounts for 11.2% and 9.2% of the national incidence and mortality...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/36A61P35/00A61P15/14
CPCA61K31/36A61K31/704A61P15/14A61P35/00A61K2300/00
Inventor 马养民陈镝惠昱昱王宁宁汪小钢陈璞雷瑞杜凯
Owner SHAANXI UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com